Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

70 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Mini-BEAM followed by BEAM and ABMT for very poor risk Hodgkin's disease.
Chopra R, Linch DC, McMillan AK, Blair S, Patterson KG, Moir D, Richards JD, Cervi P, Kinsey S, Goldstone AH. Chopra R, et al. Among authors: cervi p. Br J Haematol. 1992 Jun;81(2):197-202. doi: 10.1111/j.1365-2141.1992.tb08207.x. Br J Haematol. 1992. PMID: 1643017
Cyclophosphamide, thalidomide, and dexamethasone as induction therapy for newly diagnosed multiple myeloma patients destined for autologous stem-cell transplantation: MRC Myeloma IX randomized trial results.
Morgan GJ, Davies FE, Gregory WM, Bell SE, Szubert AJ, Navarro Coy N, Cook G, Feyler S, Johnson PR, Rudin C, Drayson MT, Owen RG, Ross FM, Russell NH, Jackson GH, Child JA; National Cancer Research Institute Haematological Oncology Clinical Studies Group. Morgan GJ, et al. Haematologica. 2012 Mar;97(3):442-50. doi: 10.3324/haematol.2011.043372. Epub 2011 Nov 4. Haematologica. 2012. PMID: 22058209 Free PMC article. Clinical Trial.
The metabolites of nitric oxide in sickle-cell disease.
Rees DC, Cervi P, Grimwade D, O'Driscoll A, Hamilton M, Parker NE, Porter JB. Rees DC, et al. Among authors: cervi p. Br J Haematol. 1995 Dec;91(4):834-7. doi: 10.1111/j.1365-2141.1995.tb05397.x. Br J Haematol. 1995. PMID: 8547126
Effects of induction and maintenance plus long-term bisphosphonates on bone disease in patients with multiple myeloma: the Medical Research Council Myeloma IX Trial.
Morgan GJ, Davies FE, Gregory WM, Szubert AJ, Bell SE, Drayson MT, Owen RG, Ashcroft AJ, Jackson GH, Child JA; National Cancer Research Institute Haematological Oncology Clinical Studies Group. Morgan GJ, et al. Blood. 2012 Jun 7;119(23):5374-83. doi: 10.1182/blood-2011-11-392522. Epub 2012 Apr 12. Blood. 2012. PMID: 22498739 Free article. Clinical Trial.
The role of maintenance thalidomide therapy in multiple myeloma: MRC Myeloma IX results and meta-analysis.
Morgan GJ, Gregory WM, Davies FE, Bell SE, Szubert AJ, Brown JM, Coy NN, Cook G, Russell NH, Rudin C, Roddie H, Drayson MT, Owen RG, Ross FM, Jackson GH, Child JA; National Cancer Research Institute Haematological Oncology Clinical Studies Group. Morgan GJ, et al. Blood. 2012 Jan 5;119(1):7-15. doi: 10.1182/blood-2011-06-357038. Epub 2011 Oct 20. Blood. 2012. PMID: 22021371 Free article. Clinical Trial.
Something fishy in the immunocompromised.
Sillito F, Cervi P, Skibinska M. Sillito F, et al. Among authors: cervi p. Br J Haematol. 2011 Apr;153(2):148. doi: 10.1111/j.1365-2141.2010.08566.x. Epub 2011 Feb 17. Br J Haematol. 2011. PMID: 21401570 Free article. No abstract available.
70 results